Bedel Financial Consulting »

Relmada Therapeutics shares owned by Bedel Financial Consulting

Quarter-by-quarter ownership of Relmada Therapeutics (RLMD) shares owned by Bedel Financial Consulting from 13F filings

Historical chart of Bedel Financial Consulting investment in Relmada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Relmada Therapeutics held by Bedel Financial Consulting consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Relmada Therapeutics by Bedel Financial Consulting

Quarter filed Position value Share count Share price at filing
2024-03-31 $47k 10k 4.65
2023-12-31 $41k 10k 4.14
2023-09-30 $30k 10k 3.00
2023-06-30 $25k 10k 2.46

More positions owned by Bedel Financial Consulting

Dimensional Etf Trust Intl Core Eqt Mk (DFAI)
Vanguard Mun Bd Fds Tax Exempt Bd (VTEB)
Microsoft Corporation (MSFT)
Apple (AAPL)
Dimensional Etf Trust Emgr Cre Eqt Mng (DFAE)
Ishares Tr Eafe Grwth Etf (EFG)
Capital Group Growth Etf Shs Creation Uni (CGGR)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Innovator Etfs Trust Us Eqt Pwr Buf (PAPR)
Ssga Active Etf Tr Spdr Tr Tactic (TOTL)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
Ishares Tr Core S&p500 Etf (IVV)
JPMorgan Chase & Co. (JPM)
Global X Fds Rate Preferred (PFFV)
Ishares Tr MRGSTR MD CP GRW (IMCG)

View all positions for Bedel Financial Consulting

Top funds holding Relmada Therapeutics

Vanguard Group
Parsons Capital Management
Opaleye Management
Palo Alto Investors
Citadel Advisors
Two Sigma Advisers
Two Sigma Investments
Point72 Asset Management
Deutsche Bank Aktiengesellschaft
Jacobs Levy Equity Management
Bank of America Corporation
Millennium Management
Guild Investment Management
Marshall Wace
Barclays

View all funds holding Relmada Therapeutics